Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Magle Chemoswed Holding AB is a pharmaceutical and chemical company based in Sweden. The company specializes in drug delivery systems, offering innovative solutions for the controlled release of pharmaceuticals. With its extensive expertise in polymer technologies, Magle Chemoswed focuses on developing products that enhance drug efficacy and patient compliance. The company operates within the global healthcare sector, working in collaboration with pharmaceutical and biotech firms to provide bespoke manufacturing and development services. This strategic position allows it to impact various therapeutic areas, including oncology, cardiovascular diseases, and neurology. By investing in cutting-edge research and development, Magle Chemoswed Holding AB plays a crucial role in advancing medical treatments and improving patient outcomes.
kr 0.05
kr 0.00 (-6.12%)
Live · 10:44 PM · Twelve Data
The business is unprofitable at the operating level (-48.06% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 19.9%, still solid. Margins contracted 54.9pp, which offsets some of the top-line progress.
ROIC dropped from 2.81% to -13.00%, capital efficiency is deteriorating. Negative free cash flow of -kr 32M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 270M
▲ +19.9% YoY
Net Income (TTM)
-kr 181M
▼ -1439.5% YoY
Op. Margin
-58.12%
▼ -54.9pp YoY
ROIC
-13.00%
▼ -15.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 76M
▼ -14.8% YoY
Op. Cash Flow (TTM)
-kr 24M
▼ -40.2% YoY
Net Debt
kr 333M
Cash & Equiv.
kr 14M
3Y CAGR: +24.8%
Continue Research
Magle Chemoswed Holding AB (MAGLE.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Magle Chemoswed Holding AB scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Magle Chemoswed Holding AB scores 15 out of 100 on Intrinsiqq's quality score, passing 1 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -58.1% operating margin and a -13.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh MAGLE.XSTO's valuation and scores 15/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.